Comparative outcome of cisplatin-capecitabine regimen with oxaliplatincapecitabine regimen in advanced gastric carcinoma: a quasi-experimental study

Comparative outcome of cisplatin-capecitabine regimen with oxaliplatin-capecitabine regimen in advanced gastric carcinoma

Authors

  • Mohammad Jahan Shams Medical Officer, Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh https://orcid.org/0000-0002-1535-259X
  • Sajib Kumar Talukdhar Medical Officer, Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Mst Hasnahena Nargis Medical Officer, Department of Gastroenterology, Mugda medical college, Dhaka, Bangladesh
  • Moumita Ghosh Resident, Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Md Masudur Rahman Resident, Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Md Zakir Hasan Medical Officer, Department of Gastroenterology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Sarwar Alam Professor, Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Md Zillur Rahman Bhuiyan Professor, Department of Clinical Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/bsmmuj.v15i3.63445

Keywords:

Gastric carcinoma, chemotherapy, quasi-experimental.

Abstract

Chemotherapy is the primary therapeutic choice for advanced gastric cancer. The goal of this study was to assess the effectiveness and toxicity of the cisplatin-capecitabine regimen versus the oxaliplatin-capecitabine regimen in treating advanced gastric cancer. Between February 2021 and March 2022, this quasi-experimental study was conducted on 64 advanced gastric cancer patients. Purposive sampling was used to include those who met the inclusion criteria and distributed them evenly between the two arms. Arm A got an injection of cisplatin (80 mg/m2 on day 1) with oral capecitabine (1000 mg/m2 b.i.d. on days 1–14), whereas arm B received an injection of oxaliplatin (130 mg/m2 on day 1) plus oral capecitabine (1000 mg/m2 b.i.d. on days 1–14), every 3 weeks for 6 cycles. A final check-up was done at 12 weeks after the treatment. In arm A, 18 (56.2%) patients exhibited partial response compared to 15 (46.9%) in arm B. Stable diseases were also reported in both arms (18.8% in arm A and 21.9% in arm B). There were 8 (25.0%) cases of progressive disease in arm A and 10 (31.2%) cases in Arm B. The median progression-free survival in arms A (5.6 months) was almost similar to arm B (5.9 months). The most prevalent toxicities in both arms were vomiting, diarrhea, anemia, neutropenia, oral mucositis, paresthesia, handfoot syndrome, and renal toxicity. There were no statistically significant variations in outcomes between the two arms. In conclusion, the cisplatincapecitabine regimen is as effective as the oxaliplatin-capecitabine regimen in advanced gastric cancer.

BSMMU J 2022; 15(3): 180-185

Downloads

Download data is not yet available.
Abstract
224
PDF
101

Downloads

Published

2023-01-16

How to Cite

Shams, M. J. ., Talukdhar, S. K. ., Nargis, M. H. ., Ghosh, M. ., Rahman, M. M. ., Hasan, M. Z. ., Alam, S. ., & Bhuiyan, M. Z. R. . (2023). Comparative outcome of cisplatin-capecitabine regimen with oxaliplatincapecitabine regimen in advanced gastric carcinoma: a quasi-experimental study: Comparative outcome of cisplatin-capecitabine regimen with oxaliplatin-capecitabine regimen in advanced gastric carcinoma. Bangabandhu Sheikh Mujib Medical University Journal, 15(3), 180–185. https://doi.org/10.3329/bsmmuj.v15i3.63445

Issue

Section

Original Article

Most read articles by the same author(s)

Similar Articles

> >> 

You may also start an advanced similarity search for this article.